Randomized phase III study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC Meeting Abstract
| Authors: | Loong, H. H. F.; Goto, K.; Solomon, B. J.; Park, K.; PeĢrol, M.; Arriola, E.; Novello, S.; Cheng, Y.; Ardizzoni, A.; Mak, M.; Santini, F. C.; Elamin, Y. Y.; Drilon, A.; Wolf, J.; Han, B.; Han, H.; Uh, M.; Puri, T.; Ilaria, V.; Zhou, C. |
| Abstract Title: | Randomized phase III study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC |
| Meeting Title: | ESMO Congress 2023 |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Oct 20-24 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-10-01 |
| Start Page: | S1303 |
| Language: | English |
| ACCESSION: | WOS:001087480203545 |
| DOI: | 10.1016/j.annonc.2023.10.059 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA4 -- Source: Wos |
